The SARS-CoV-2 Omicron variant (B.1.1.529) has multiple spike protein mutations 1 , 2 that
contribute to viral escape from antibody neutralization 3 , 4 , 5 – 6 and reduce vaccine …

The SARS-CoV-2 Omicron variant has multiple Spike (S) protein mutations that contribute to
escape from the neutralizing antibody responses, and reducing vaccine protection from …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants of concern (VOCs)
exhibit escape from neutralizing antibodies, causing concern about vaccine effectiveness. …

The SARS-CoV-2 Omicron variant escapes neutralizing antibodies elicited by vaccines or
infection. However, whether Omicron triggers cross-reactive humoral responses to other …

The Janssen (Johnson & Johnson) Ad26.COV2.S non-replicating viral vector vaccine has
been widely deployed for COVID-19 vaccination programs in resource-limited settings. Here …

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve,
several variants of concern (VOCs) have arisen which are defined by multiple mutations in their …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.4 and BA.5
variants caused major waves of infections. Here, we assess the sensitivity of BA.4 to …

The kinetics of Fc-mediated functions following SARS-CoV-2 infection or vaccination in
people living with HIV (PLWH) are not known. We compared SARS-CoV-2 spike-specific Fc …

SARS-CoV-2 variants of concern (VOCs) differentially trigger neutralizing antibodies with
variable cross-neutralizing capacity. Here we show that unlike SARS-CoV-2 Omicron BA.1, …

Background HIV-infected patients have an increased risk of renal disease. Current first-line
antiretroviral therapy contains tenofovir disoproxil fumarate (TDF), which has nephrotoxic …